At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Pegylated Irinotecan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pegylated Irinotecan, and 1 other intervention for Recurrent Small Cell Lung Carcinoma. Completed, enrolled 38 participants across 3 sites.
Detailed Summary
This phase II trial studies how well pegylated irinotecan NKTR 102 works in treating patients with small cell lung cancer that has returned after a period of improvement. Pegylated irinotecan NKTR 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Small Cell Lung Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Nektar Therapeutics
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartAug 2013
Primary CompletionJul 2017
Study CompletionFeb 2020
TodayJul 2026
First PostedJun 12, 2013
Enrollment StartAug 29, 2013
Primary CompletionJul 18, 2017
Study CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.1 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pegylated Irinotecandrug
Given IV
Pharmacological Studyother
Correlative studies